No annual revenue total was found in ESTRELLA IMMUNOPHARMA, INC.'s SEC filings.
Estrella Immunopharma, Inc. (ESLA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income (TTM)
$-10.01M
Operating cash flow (TTM)
$-9.38M
Free cash flow
—
EPS (TTM)
$-0.25
Dividend per share
None
Shares outstanding
42.67M
+18.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ESLA (Nasdaq), ESLAW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp. (until Sep 20, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Jun 30, 2024 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|
| Operating income | -$13.1M | -$7.3M | -$1.6M | -$249,146 |
| Net income | -$13.1M | -$7.3M | -$996,104 | -$247,718 |
| Diluted EPS | -$0.35 | -$0.27 | — | — |
| Operating cash flow | -$1.8M | -$16.1M | -$1.0M | -$316,158 |
| Total assets | $3.2M | $4.5M | $9.7M | $45.8M |
| Total liabilities | $13.5M | $180,701 | $2.7M | $1.6M |
| Stockholders' equity | -$10.4M | $4.3M | -$2.3M | -$1.0M |
| Cash and investments | $1.4M | $4.2M | $40,802 | $478,868 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 29, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2026 | Jun 29, 2026 |
| 10-Q | Quarterly report | May 18, 2026 | Mar 31, 2026 |
All 258 Estrella Immunopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.